Michael Lee is an Independent Director of Fate Therapeutics Inc. Mr. Lee has served as Co-Founder and Portfolio Manager at Redmile Group, LLC since 2007. Prior to Redmile, Mr. Lee worked as a biotechnology investor at Steeple Capital, and as an analyst at Welch Capital Partners and Prudential Equity Group. Mr. Lee holds a B.S. in Molecular and Cellular Biology from the University of Arizona. The Board of Directors has determined that Mr. Lee’s extensive business and leadership experience in the biotechnology industry qualifies him to serve as a member of our Board of Directors.
As the Independent Director of Fate Therapeutics Inc, the total compensation of Michael Lee at Fate Therapeutics Inc is $232,483. There are 13 executives at Fate Therapeutics Inc getting paid more, with John Wolchko having the highest compensation of $10,721,000.
Michael Lee is 41, he's been the Independent Director of Fate Therapeutics Inc since 2018. There are 16 older and no younger executives at Fate Therapeutics Inc. The oldest executive at Fate Therapeutics Inc is William Rastetter, 72, who is the Independent Chairman of the Board.
Michael's mailing address filed with the SEC is 1 Letterman Dr, San Francisco, CA 94129, USA.
Over the last 11 years, insiders at Fate Therapeutics Inc have traded over $48,476,146 worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth $162,421,037 . The most active insiders traders include Group, Llc Green Jeremy Red..., Associates V Lpvenrock Part..., and Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $384,496. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth $2,678.
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
Fate Therapeutics Inc executives and other stock owners filed with the SEC include: